Chin-Ming Chang serves as the Chief Executive Officer of TaiMed Biologics, a publicly traded biotechnology company renowned for its pioneering work in developing and manufacturing monoclonal antibody drugs specifically targeting HIV treatment. Under his leadership, TaiMed has made significant strides in advancing innovative therapeutic solutions...
Chin-Ming Chang serves as the Chief Executive Officer of TaiMed Biologics, a publicly traded biotechnology company renowned for its pioneering work in developing and manufacturing monoclonal antibody drugs specifically targeting HIV treatment. Under his leadership, TaiMed has made significant strides in advancing innovative therapeutic solutions that address critical unmet medical needs in the HIV space. With a robust background in drug development and regulatory affairs, Chang has successfully overseen the commercialization of several pharmaceutical products, ensuring that they meet stringent FDA regulations and quality standards.
One of the key projects under Chang’s direction is the enhancement of TaiMed's in-house manufacturing technologies, which has positioned the company as a leader in cGMP (current Good Manufacturing Practice) mAb manufacturing. This initiative not only strengthens TaiMed's operational capabilities but also expands its contract development and manufacturing organization (CDMO) services, allowing the company to offer comprehensive solutions to other biotech firms seeking reliable and efficient manufacturing partnerships.
Chang’s expertise in new business development, formulation, and validation processes has been instrumental in driving TaiMed's growth trajectory. His strategic vision encompasses not only the advancement of monoclonal antibody therapies but also the exploration of innovative applications in ophthalmics and parenteral drug delivery systems. As a result, TaiMed Biologics is well-positioned to leverage its cutting-edge technologies and regulatory expertise to navigate the complexities of the biotechnology landscape, ultimately improving patient outcomes and contributing to the global fight against HIV.
